Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients.

Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University), Monica Guffanti(Vita-Salute San Raffaele University), Giulia Morsica(Vita-Salute San Raffaele University), Nicola Gianotti(Vita-Salute San Raffaele University), Enzo Boeri(National Cancer Institute), A De Bona
PubMed
January 14, 1999
Cited by 8

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
|The Lancet|1992|393
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus–Infected Women: Effect of Highly Active Antiretroviral Therapy
|The Journal of Infectious Diseases|2001|173